Saturday 17 October 2026 Export MDGL’s income statement to Excel — free account

Madrigal Pharmaceuticals, Inc.

Madrigal Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $958.4 million, up 432.1% from fiscal 2024. In the quarter to June 2026, revenue grew 71.2%, EPS fell 32.9%, free cash flow grew 140.5% and total debt rose 187.9%, each against the same quarter a year earlier.

449.74 10.07 −2.19%

Follow MDGL

Alert me

Market cap: $10.6B
P/E: 0.0×
Fwd P/E: −71.3×
Dividend yield: —
F-score: n/a
Altman Z: 10.48
Beneish M: 0.50
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 81.48

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	3	4	9	—	6	—	2	1	1	1	1	—

Insider Ownership 26.09%

Capital & Financial Ratios $m

Market Cap 10,620.00

Revenue 1,283.94

Net Income (325.09)

Free Cash Flow (206.28)

Net Debt (498.11)

Current Ratio 3.20

Debt/Equity 0.65

P/E ratio 0.00

Fwd P/E (71.30)

P/S ratio 10.21

P/B ratio 25.03

Past 5Y EPS Growth —

This Y EPS Growth 53.15%

Next Y EPS Growth 194.92%

Next Y revenue growth 59.33%

Next 5Y EPS Growth 0.00%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

P/B against its own 10 years 84.62%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2025	Powerpack
2024	Powerpack
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2017	Powerpack

predictions special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	634	931	989	839
Receivables	—	54	134	192
Inventory	—	34	75	99
Other	—	—	—	—
	637	1,033	1,246	1,199

	2023	2024	2025	Q'26
Payables	28	44	49	35
ST’ Debt	—	—	—	—
Other	—	—	—	—
	119	169	310	374

Compound Annual Growth %

	10y	5y	3y
Sales	—	—	(89.94%)
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	0.00%	20.22%	45.07%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	311	364	—	—	—
’25	137	213	287	321	958

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(167)	23	—	—	—
’25	(89)	(47)	80	(133)	(190)
’24	(149)	(135)	(67)	(104)	(456)
’23	(84)	(75)	(85)	(80)	(324)
’22	(50)	(57)	(59)	(59)	(225)
’21	(43)	(47)	(46)	(48)	(184)
’20	(31)	(24)	(48)	(55)	(158)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(171)	19	—	—	—
’25	(89)	(47)	76	(133)	(193)
’24	(150)	(140)	(68)	(105)	(462)
’23	(84)	(75)	(85)	(81)	(326)
’22	(50)	(57)	(59)	(59)	(225)
’21	(43)	(47)	(46)	(48)	(184)
’20	(31)	(24)	(48)	(55)	(158)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(3.25)	(1.99)	—	—	—
’25	(2.61)	(1.50)	(5.08)	(2.57)	(12.85)
’24	(7.38)	(7.10)	(4.92)	(2.71)	(21.90)
’23	(4.23)	(4.69)	(5.34)	(5.68)	(19.99)
’22	(3.36)	(4.14)	(4.75)	(4.98)	(17.23)
’21	(3.32)	(3.72)	(3.79)	(3.78)	(14.63)
’20	(2.34)	(3.18)	(3.75)	(3.82)	(13.09)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	5.25	13.09	90.56	82.31	56.82	68.56	52.33	119.76	168.25	265.00	Analyst estimates 2026–2028 Powerpack
	High	18.24	101.00	325.98	148.18	137.28	142.62	315.45	322.67	368.29	615.00
People
People	Employees	8	8	17	29	42	71	92	376	528	915
	Revenue/emp, $m	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.34	1.05
Income, $m
Income, $m	Revenue	—	—	—	—	—	—	—	—	180	958
	Gross margin, %	0.00	0.00	0.00	0.00	0.00	0.00	0.00	—	96.54	94.14
	EBT	(26)	(31)	(33)	(84)	(202)	(242)	(295)	(374)	(466)	(288)
	EBT margin, %	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	(258.64)	(30.08)
	Net income	(26)	(31)	(33)	(84)	(202)	(242)	(295)	(374)	(466)	(288)
	Depreciation	0	0	0	0	0	0	1	3	3	6
Per share, $
Per share, $	Revenue	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	8.47	42.72
	Earnings	(5.07)	(2.54)	(2.22)	(5.45)	(13.09)	(14.63)	(17.23)	(19.99)	(21.90)	(12.85)
	Cash flow	(3.38)	(1.82)	(1.72)	(2.70)	(10.20)	(11.12)	(13.12)	(17.35)	(21.42)	(8.45)
	Capex	0.13	(0.01)	0.00	(0.01)	(0.02)	(0.01)	(0.01)	(0.08)	(0.30)	(0.15)
	Free cash flow	(3.25)	(1.83)	(1.73)	(2.71)	(10.22)	(11.14)	(13.13)	(17.43)	(21.72)	(8.60)
	Book value	7.00	14.88	32.24	27.06	15.54	11.86	11.52	21.69	35.46	26.87
	Shares, m	5	12	15	15	15	17	17	19	21	22
Valuation, ×
Valuation, ×	P/E	—	—	—	—	—	—	—	—	0.00	0.00
	P/S	—	—	—	—	—	—	—	—	0.00	13.63
	P/B	—	—	—	—	—	—	—	—	8.70	21.68
	EV/Sales	—	—	—	—	—	—	—	—	0.00	12.95
	EV/FCF	—	—	—	—	—	—	—	—	(12.45)	(64.00)
Cash, $m
Cash, $m	Operating cash flow	(18)	(22)	(26)	(42)	(158)	(184)	(225)	(324)	(456)	(190)
	Capex	1	0	0	0	0	0	0	(1)	(6)	(3)
	Free cash flow	(17)	(22)	(26)	(42)	(158)	(184)	(225)	(326)	(462)	(193)
Balance, $m
Balance, $m	Working capital	36	182	477	415	239	195	245	519	864	935
	Total debt	—	—	—	0	0	0	49	115	118	340
	Net debt	(40)	(192)	(484)	(439)	(284)	(270)	(309)	(519)	(814)	(649)
	Shareholders’ equity	36	182	477	417	240	196	197	405	754	603
Returns, %
Returns, %	ROA	(126.95)	(26.68)	(9.68)	(18.10)	(55.48)	(86.32)	(92.89)	(74.49)	(55.37)	(25.05)
	ROIC	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	ROE	422.09	(28.49)	(9.95)	(18.79)	(61.61)	(110.92)	(150.12)	(123.98)	(80.35)	(42.49)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
CORT Corcept Therapeutics Incorporated	$12.3B	212×	139×	+31.74% (above 0%: growing)	+21.21% (above 0%: growing)	−29.89% (below 0%: shrinking)	98.41%	16.12%	Compare
SMMT Summit Therapeutics PLC	$12.3B	— (loss-making)	— (loss-making)	−100.00% (below 0%: shrinking)	n/m	−112.80% (below 0%: shrinking)	0.00%	0.00%	Compare
TECH Bio-Techne Corp	$11.4B	62.0×	37.6×	+1.33% (above 0%: growing)	n/m	−6.83% (below 0%: shrinking)	65.82%	23.13%	Compare
BMRN BioMarin Pharmaceutical Inc.	$10.9B	144×	16.1×	+19.91% (above 0%: growing)	−81.60% (below 0%: shrinking)	−20.28% (below 0%: shrinking)	79.51%	11.21%	Compare
MDGL Madrigal Pharmaceuticals, Inc.	$10.6B	— (loss-making)	— (loss-making)	+71.17% (above 0%: growing)	n/m	+140.54% (above 0%: growing)	89.02%	(15.46%)
IBRX ImmunityBio, Inc.	$10.6B	— (loss-making)	— (loss-making)	+93.91% (above 0%: growing)	n/m	+13.38% (above 0%: growing)	99.42%	(120.41%)	Compare
PCVX Vaxcyte, Inc.	$10.3B	— (loss-making)	—	—	n/m	−92.55% (below 0%: shrinking)	0.00%	0.00%	Compare
KRYS Krystal Biotech, Inc.	$9.8B	38.3×	38.6×	+24.14% (above 0%: growing)	+39.10% (above 0%: growing)	+40.14% (above 0%: growing)	94.60%	49.00%	Compare
KYMR Kymera Therapeutics, Inc.	$9.0B	— (loss-making)	— (loss-making)	+466.40% (above 0%: growing)	n/m	+9.97% (above 0%: growing)	100.00%	(116.32%)	Compare
Median of peers	$10.7B	103×	38.1×	+24.14%	+21.21%	−13.55%	87.05%	5.61%

All 614 Biotechnology stocks →

Madrigal Pharmaceuticals, Inc. (MDGL) key facts

Strength: Madrigal Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $958.4 million, up 432.1% from fiscal 2024.
Madrigal Pharmaceuticals, Inc. (MDGL) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, MDGL traded at $449.74, a market capitalization of $10.6 billion.
Return on equity was −42.5% and debt-to-equity 0.65.
Its Altman Z-score is 10.48 (safe zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.